Melanoma

T cells
#Cancer research #Icahn School of Medicine #Immunotherapy #Melanoma #mRNA #Oncology #Solid tumours

RNA strategy activates dendritic cells and eradicates melanoma tumours

Investigators at the Icahn School of Medicine at Mount Sinai have designed an RNA-based strategy to activate dendritic cells that eradicated tumours and prevented their recurrence in mouse models of melanoma. The findings, which suggest that the approach has the potential to be effective against tumours… Read More

#Cancer Research #Editor's Choice #News

Vitamin supplements
#Cancer research #Immunotherapy #Melanoma #Oncology #Skin cancer

Vitamin D levels impact response to immunotherapy in melanoma

New research indicates that for patients with advanced skin cancer, it may be important to maintain normal vitamin D levels when receiving treatment with immune checkpoint inhibitors. The findings are published in CANCER, a peer-reviewed journal of the American Cancer Society. Vitamin D has… Read More

#Cancer Research #News

T cells attack cancer cell
#AACR 2023 #Cancer research #Melanoma #Oncology #Purple Biotech #Tumour microenvironment (TME)

New drug could help overcome tumour resistance to treatment

New study results have demonstrated the potential of a new drug to reprogramme the immune profile in the tumour microenvironment (TME) and convert resistant tumours to responders to Immune Checkpoint Blockage (ICB) therapies. Purple Biotech shared the new results at the American Association for Cancer Research… Read More

#Cancer Research #News

Testing visual acuity
#Aura Biosciences #Cancer research #Melanoma #Oncology #Ophthalmology #Phase II trial

Choroidal melanoma drug preserved vision in Phase II study

Aura Biosciences has announced positive interim Phase II safety and efficacy data for belzupacap sarotalocan (bel-sar) as a first-line treatment for patients with early-stage choroidal melanoma with suprachoroidal administration.  The results showed a statistically significant reduction in tumour growth rate compared to each patient’s documented growth rate… Read More

#Cancer Research #News

Skin cancer cells
#AI / data analytics / healthtech / informatics #Cancer #Cancer research #Cell #Melanoma #Oncology

Study reveals impact of cancer cell size on treatment response

Cancer cells can shrink or super-size themselves to survive drug treatment or other challenges within their environment, researchers have discovered.  Scientists at The Institute of Cancer Research, London, combined biochemical profiling technologies with mathematical analyses to reveal how genetic changes lead to differences in the size of… Read More

#Cancer Research #News

#Cancer research #Immunology / Virology & Vaccines #Melanoma #Merck #Moderna #mRNA #mRNA-based vaccines

mRNA cancer vaccine meets primary efficacy endpoint

Personalised mRNA vaccine mRNA-4157/V940 has demonstrated a clinically meaningful improvement in patients with late-stage melanoma.  The vaccine, in combination with Keytruda, met its primary endpoint of recurrence-free survival (RFS) for the adjuvant treatment of patients with stage III/IV melanoma following complete resection.  Adjuvant treatment with… Read More

#Cancer Research #News

RNA vaccine
#Cancer research #Cancer vaccine #Immuno-oncology #Immunology / Virology & Vaccines #Melanoma #Merck #Moderna #mRNA

Merck and Moderna to develop personalised cancer vaccine

Merck (MSD) and Moderna have revealed plans to work together on the development and commercialisation of an investigational personalised cancer vaccine. The companies will report data from the ongoing Phase II trial of mRNA-4157/V940 in combination with KEYTRUDA in high-risk melanoma later this year. “We have been collaborating with Merck… Read More

#Cancer Research #News #Trending News

Melanoma or skin cancer
#Immuno-oncology #Melanoma #Oncology

T cell therapy for melanoma shows promise 

New trial data has shown that using a patient’s own immune cells could be a powerful immunotherapy for metastatic melanoma, an aggressive skin cancer.  The TIL (tumour-infiltrating lymphocytes) trial compared T cell therapy to standard immunotherapy with the checkpoint inhibitor ipilimumab.  The results of the… Read More

#Cancer Research #News

Melanoma
#Cancer research #Melanoma #Skin cancer

Researchers slow down spread of melanoma 

Scientists from Tel Aviv University have deciphered the mechanism that enables skin cancer to metastasise to the brain and were able to delay the spread of the disease by 60-80% using existing treatments.  Once melanoma, or skin cancer, spreads to the brain, it becomes extremely aggressive. Patients… Read More

#Cancer Research #News